This document is a correction notice for an article titled "Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis." The authors of the original article discovered that Figure 4 was a duplicate of Figure 3. This correction article provides the correct versions of both figures. The corrected article includes graphs showing progression-free survival (PFS) and overall survival (OS) based on PD-L1 CPS classes and ECOG PS classes in patients treated with pembrolizumab-based chemoimmunotherapy and pembrolizumab monotherapy. The original article has been updated with these corrections. [Extracted from the article]